Phase I and II trials that study the effect of CAR-T on B-cell maturation antigen (BCMA) or CD22 have shown potent antitumor activity for multiple myeloma (MM) and acute lymphoblastic leukemia (ALL), respectively [6,7,8,9,10,11,12]. This evidence concerns the gene TNFRSF17 and acute lymphoblastic leukemia.